|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0009013,
umls-concept:C0017262,
umls-concept:C0020964,
umls-concept:C0039194,
umls-concept:C0062863,
umls-concept:C0185117,
umls-concept:C0536940,
umls-concept:C1332714,
umls-concept:C1413787,
umls-concept:C1511636,
umls-concept:C1704858,
umls-concept:C1707520,
umls-concept:C1880022,
umls-concept:C2825965,
umls-concept:C2911684
|
|
pubmed:dateCreated |
2004-12-16
|
|
pubmed:abstractText |
NY-ESO-1 is one of the most immunogenic cancer antigens known to date, eliciting spontaneous immune responses in approximately 50% of patients with NY-ESO-1+ cancers. Spontaneous CD4+ and CD8+ T cell responses were found in patients with detectable NY-ESO-1 serum antibody, indicating an integrated type of immune response induced by NY-ESO-1+ malignancies. A close association between spontaneous NY-ESO-1 immunity and the HLA-DP4 allele was suggested in a recent study. To address these results, we assessed the NY-ESO-1 antibody and HLA-DP4 status of 102 patients with NY-ESO-1+ malignancies. However, no correlation between HLA-DP4 and NY-ESO-1 immunity was found. To explore the role of HLA-DP4-restricted CD4+ T cells in cancer immunity, we established HLA-DP4- restricted NY-ESO-1-specific CD4+ T cell clones by limiting dilution and repeated stimulation with NY-ESO-1 peptide p157-170 from NY-ESO-1 seropositive patients. A subset of CD4+ T cell clones was reactive with naturally processed NY-ESO-1 presented by autologous DCs that were pulsed with recombinant NY-ESO-1 protein, lysates of NY-ESO-1-expressing tumor cell lines, or transduced with recombinant NY-ESO-1 viral constructs in ELISPOT assays. Three different CD4+ T cell clones were used to mediate the specific lysis of allogeneic HLA-DP4+ Epstein-Barr virus-transformed B cells (EBV-B) pulsed with NY-ESO-1 p157-170. The Th1 phenotype and effector functions of the CD4+ T cell clones described here provide an important rationale for the activation of antigen-specific CD4+ T cells along with CD8+ T cells in cancer vaccination strategies.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Dec
|
|
pubmed:issn |
1424-9634
|
|
pubmed:author |
pubmed-author:ArandMichaelM,
pubmed-author:AtanackovicDjordjeD,
pubmed-author:BenderArminA,
pubmed-author:ChenYao-TsengYT,
pubmed-author:GnjaticSachaS,
pubmed-author:HuarteEduardoE,
pubmed-author:JägerDirkD,
pubmed-author:JägerElkeE,
pubmed-author:KarbachJuliaJ,
pubmed-author:KnuthAlexanderA,
pubmed-author:OldLloyd JLJ,
pubmed-author:RitterGerdG,
pubmed-author:SkipperJonathanJ
|
|
pubmed:issnType |
Electronic
|
|
pubmed:day |
16
|
|
pubmed:volume |
4
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
15
|
|
pubmed:dateRevised |
2011-11-17
|
|
pubmed:meshHeading |
pubmed-meshheading:15600300-Antigen-Presenting Cells,
pubmed-meshheading:15600300-Antigens, Neoplasm,
pubmed-meshheading:15600300-CD4-Positive T-Lymphocytes,
pubmed-meshheading:15600300-CD8-Positive T-Lymphocytes,
pubmed-meshheading:15600300-Carcinoma, Non-Small-Cell Lung,
pubmed-meshheading:15600300-Cell Line, Tumor,
pubmed-meshheading:15600300-Clone Cells,
pubmed-meshheading:15600300-Female,
pubmed-meshheading:15600300-Gene Expression Regulation, Neoplastic,
pubmed-meshheading:15600300-HLA-DP Antigens,
pubmed-meshheading:15600300-HLA-DP beta-Chains,
pubmed-meshheading:15600300-Humans,
pubmed-meshheading:15600300-Immunophenotyping,
pubmed-meshheading:15600300-Lung Neoplasms,
pubmed-meshheading:15600300-Melanoma,
pubmed-meshheading:15600300-Membrane Proteins,
pubmed-meshheading:15600300-Neoplasms,
pubmed-meshheading:15600300-Ovarian Neoplasms,
pubmed-meshheading:15600300-Receptors, Interleukin-2,
pubmed-meshheading:15600300-T-Lymphocyte Subsets,
pubmed-meshheading:15600300-T-Lymphocytes, Cytotoxic
|
|
pubmed:year |
2004
|
|
pubmed:articleTitle |
HLA-DP4 expression and immunity to NY-ESO-1: correlation and characterization of cytotoxic CD4+ CD25- CD8- T cell clones.
|
|
pubmed:affiliation |
II. Medizinische Klinik, Hämatologie-Onkologie, Krankenhaus Nordwest, Frankfurt, Germany.
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|
